Fam-trastuzumab deruxtecan-nxki latest price in 2023

Fam-trastuzumab deruxtecan-nxki is an injection used to treat a certain type of breast cancer that cannot be removed with surgery, has spread to other parts of the body, or has come back after treatment for another type of breast cancer. It is also used to treat certain types of stomach cancer in adults who have spread to nearby tissue or other parts of the body after receiving another treatment. Trastuzumab is also used to treat a certain type of non-small cell lung cancer in adults that cannot be removed with surgery or that has spread to other parts of the body after receiving another treatment.

Trastuzumab belongs to a class of drugs called antibody-drug conjugates. It works by killing cancer cells. Trastuzumab is given intravenously (into a vein) by a doctor or nurse at a hospital or medical facility over 30 or 90 minutes. Injections are usually given every every 3 weeks for as long as the doctor advises the patient to receive treatment. Depending on the patient's response to the drug and any side effects experienced, doctors may delay or stop treatment with trastuzumab, or use other medications. Nausea and vomiting may occur during and after medication, and your doctor may give you another medicine to help prevent nausea and vomiting.

Detrastuzumab is a new type of injectable anti-cancer drug. The original drug has been launched in China, but it has not yet entered the scope of medical insurance. It is a strictly controlled drug. The domestic price is not yet clear, and its purchase is restricted. The Hong Kong version of DetrastuzumabSpecifications100mg per box may cost more than 10,000 yuan, and the Hong Kong original versionTrastuzumabOriginal drug specificationsThe price of 100 mg per box may be around RMB 15,000 (the price may fluctuate due to the exchange rate). The drug ingredients of the two are basically the same. There is currently no generic version of Trastuzumab produced and launched. For more specific prices and drug information, please consult the medical consultant of the drug.